Tags : Chemotherapy

Merck’s Keytruda + Chemotherapy Receive EU’s Approval for Metastatic Squamous

Shots: The approval is based on P-III KEYNOTE-407 study assessing Keytruda + carboplatin/nab paclitaxel vs carboplatin/nab paclitaxel monothx. in ratio (1:1) in patients with msqNSCLC regardless of PD-L1 expression  The P-III KEYNOTE-407 results: ORR (58% vs 38%); mDOR (7.7mos. vs 4.8mos.); improves PFS with reduction in death (44%), improvement in OS (36%) Keytruda (pembrolizumab) 200mg […]Read More